@article{1a9e99ccb41144c8a7a9836efe530be3,
title = "Roxadustat markedly reduces myocardial ischemia reperfusion injury in mice",
abstract = "Background: Ischemic preconditioning (IPC) is an effective procedure to protect against ischemia/reperfusion (I/R) injury. Hypoxia-inducible factor-1α (Hif-1α) is a key molecule in IPC, and roxadustat (RXD), a first-in-class prolyl hydroxylase domain-containing protein inhibitor, has been recently developed to treat anemia in patients with chronic kidney disease. Thus, we investigated whether RXD pretreatment protects against I/R injury. Methods and Results: RXD pretreatment markedly reduced the infarct size and suppressed plasma creatinine kinase activity in a murine I/R model. Analysis of oxygen metabolism showed that RXD could produce ischemic tolerance by shifting metabolism from aerobic to anaerobic respiration. Conclusions: RXD pretreatment may be a novel strategy against I/R injury.",
author = "Hiroko Deguchi and Masataka Ikeda and Tomomi Ide and Tomonori Tadokoro and Soichiro Ikeda and Kosuke Okabe and Akihito Ishikita and Keita Saku and Shouji Matsushima and Hiroyuki Tsutsui",
note = "Funding Information: This work was supported by JSPS KAKENHI grants (M. Ikeda: 16H07049 and 18K15892, T. Ide: 17K09582, H. Tsutsui: 15H04815), and research grants from the Takeda Science Foundation (M. Ikeda); the Uehara Memorial Foundation (M. Ikeda); the Japan Foundation for Applied Enzymology (VBIC: Vascular Biology of Innovation) (M. Ikeda); YOKOYAMA Foundation for Clinical Pharmacology (M. Ikeda, YRY-1911); MSD Life Science Foundation, Public Interest Incorporated Foundation (M. Ikeda); and the AMED (grant no. 19ek0109339h0002: H. Tsutsui). Funding Information: H. Deguchi, T. Tadokoro, S. Ikeda, K. Okabe, A. Ishikita, and S. Matsushima have nothing to declare. K. Saku received a consultant fee from Abiomed Japan K.K. H. Tsutsui received a consultant fee from Nippon Boehringer, Bayer Yakuhin, Novartic Pharma, and Ono Pharmaceutical. H. Tsutsui received remuneration from MSD K.K., Astellas Pharma Inc., Pfizer Japan Inc., Bristol-Myers Squibb Company, Otsuka Pharmaceutical Co., Ltd., Daiichi Sankyo Co., Ltd., Mitsubishi-Tanabe Pharma Corporation, Nippon Boehringer Ingellheim Co., Ltd., Takeda Pharmaceutical Company Limited, Bayer Yakuhin, Ltd., Novartis Pharma K.K., Kowa Pharmaceutical Co. Ltd., and Teijin Pharma Ltd. H. Tsutsui received a manuscript fee from Medical View and Nippon Rinsho. K. Saku received research funding from Omron Healthcare Co. H. Tsutsui received research funding from Nippon Boehringer, Mitsubishi-Tanabe Pharma, Japan Tobacco, Daiichi Sankyo, IQVIA Services Japan, Acterion Pharmaceuticals Japan, and Omron Healthcare. M. Ikeda received scholarship funds from Takeda Science Foundation, the Uehara Memorial Foundation, the Japan Foundation for Applied Enzymology (VBIC: Vascular Biology of Innovation), the YOKOYAMA Foundation for Clinical Pharmacology (YRY-1911), MSD Life Science Foundation, and the Public Interest Incorporated Foundation. H. Tsutsui has an endowed department by Acterion Pharmaceuticals Japan. Publisher Copyright: {\textcopyright} 2020 Japanese Circulation Society. All rights reserved.",
year = "2020",
doi = "10.1253/circj.CJ-19-1039",
language = "English",
volume = "84",
pages = "1028--1033",
journal = "Circulation Journal",
issn = "1346-9843",
publisher = "Japanese Circulation Society",
number = "6",
}